Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) ...
Hosted on MSN

Synaffix and Qurient enter licensing deal for dual-payload ADC

Synaffix, a company of Swiss drugmaker Lonza, has entered into a licensing agreement with South Korean biopharmaceutical firm Qurient to develop a dual-payload antibody-drug conjugate (ADC). Synaffix ...
MarketWatch

Phrontline Biopharma Raises $60 Million in Pre-A+ Financing to Advance Global Development of Bispecific and Dual-Payload ADCs

The MarketWatch News Department was not involved in the creation of this content. SHANGHAI and SUZHOU, China, Nov. 24, 2025 /PRNewswire/ -- Phrontline Biopharma ("Phrontline"), a next-generation ...
Business Wire

CrossBridge Bio Secures $10 Million Financing to Advance the Development of Next-Generation Dual-Payload ADC Therapies

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing of a $10 million ...
KXAN

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

SAN FRANCISCO and SUZHOU, China, April 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
Business Insider

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...
Seeking Alpha

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs) ...
Morningstar

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary ...
AHA/ASA Journals

HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance

BACKGROUND: The entrance of naive T cells into lymph nodes (LNs) is a crucial step for induction of heart transplant acceptance under costimulatory blockade. Specialized blood vessels within the LN ...